about
Using Pharmacogenomic Databases for Discovering Patient-Target Genes and Small Molecule Candidates to Cancer TherapyPrecision medicine: from pharmacogenomics to pharmacoproteomicsReconciling evidence-based medicine and precision medicine in the era of big data: challenges and opportunitiesApplications of chemogenomic library screening in drug discoveryThe challenges of tumor genetic diversity.TANDEM: a two-stage approach to maximize interpretability of drug response models based on multiple molecular data types.Using Big Data to Discover Diagnostics and Therapeutics for Gastrointestinal and Liver Diseases.Synthetic lethality: emerging targets and opportunities in melanoma.Whole-Genome Sequence of the Metastatic PC3 and LNCaP Human Prostate Cancer Cell Lines.Reversal of cancer gene expression correlates with drug efficacy and reveals therapeutic targetsSystematic assessment of multi-gene predictors of pan-cancer cell line sensitivity to drugs exploiting gene expression data.Robust in-silico identification of cancer cell lines based on next generation sequencing.A tool for discovering drug sensitivity and gene expression associations in cancer cells.COSMIC: somatic cancer genetics at high-resolution.The epigenomic basis of common diseases.TP53 mutations, expression and interaction networks in human cancersGuidance to rational use of pharmaceuticals in gallbladder sarcomatoid carcinoma using patient-derived cancer cells and whole exome sequencing.Transcriptome modeling and phenotypic assays for cancer precision medicine.A 13-gene expression-based radioresistance score highlights the heterogeneity in the response to radiation therapy across HPV-negative HNSCC molecular subtypes.Genomic Determinants of Protein Abundance Variation in Colorectal Cancer Cells.Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance.HIT'nDRIVE: patient-specific multidriver gene prioritization for precision oncology.Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.Progress towards a public chemogenomic set for protein kinases and a call for contributions.Machine learning for epigenetics and future medical applications.Colorectal Cancer Cell Line Proteomes are Representative of Primary Tumors and Predict Drug Sensitivity.Analysis of renal cancer cell lines from two major resources enables genomics-guided cell line selection.Synthetic lethality and cancer.Combinatorial Screening of Pancreatic Adenocarcinoma Reveals Sensitivity to Drug Combinations Including Bromodomain Inhibitor Plus Neddylation Inhibitor.A landscape of synthetic viable interactions in cancer.Looking beyond the cancer cell for effective drug combinations.Marked for death: targeting epigenetic changes in cancer.Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.The Epitranscriptome of Noncoding RNAs in Cancer.Cell-type deconvolution in epigenome-wide association studies: a review and recommendations.Epigenetic loss of the RNA decapping enzyme NUDT16 mediates C-MYC activation in T-cell acute lymphoblastic leukemia.A novel molecular diagnostics platform for somatic and germline precision oncology.CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer.Heterogeneity Aware Random Forest for Drug Sensitivity Prediction.Copy number rather than epigenetic alterations are the major dictator of imprinted methylation in tumors.
P2860
Q1632589-88577A66-6E8F-43E6-9579-4793947C7287Q16880225-6F789F98-A6A9-44D2-B106-DE880AA437A3Q17577870-DF2F04AC-C2BE-4557-B6E4-77B55F3D24BBQ17578676-9E422581-573E-48EC-94ED-B4D90C7CFDB2Q1881253-5CABD8C0-7ED7-42D9-BB33-3F73CC4F1EC4Q27555640-3E808B32-5B79-4835-B470-18870DDD27E7Q27902869-71ADB36C-89FA-4F80-88E1-286ADAA8AC62Q28199352-B2FF15D2-B0A5-408B-A4D8-FC41E939BF7AQ28308636-80DAF59D-67FA-42DC-B19B-C60E03861C78Q28334584-E5D692D9-D458-42D0-A9F3-CE53743B0BF5Q28334700-DE3083D7-D6F7-4DB9-AF32-6BBE1EDB9A89Q28473037-715C0AA5-A152-4B9E-A213-1B7F7BF340E6Q28473066-83D7A2D3-8340-440E-9AE9-D4AC2A33FA00Q28519412-A0D49FEE-CF02-4F58-9133-94B5C6873A34Q28872477-FB684206-A294-44DB-B491-780F530F51DCQ29511023-85FFC31A-379B-4D61-BA00-7BC237BE18FCQ29511246-B76231E2-5D23-4ED9-8C2E-26D9EBE21E47Q29958043-E6A8AAF8-70E1-4631-94DF-E815DC748315Q38098914-A770B620-A2D5-4DB7-97EA-EA3DB0E9F0E3Q38568854-D652DF67-AEB3-4664-A0C9-FA430213039CQ4215980-0AF78C62-16BC-49C9-9499-CEFA401FA571Q4649310-C483776A-E80A-48C6-BA51-3D7FFFEC57B5Q4649475-7BC48381-F296-4B66-83EA-5C81DFAD3318Q50432263-0C10F0FA-EA39-4675-BD2A-12931A8F0A78Q50952937-51F8C877-2433-4E18-B614-130534BD9D4DQ51838638-660F09E9-84CA-4FE5-8317-E1E09BEC0BB7Q51951823-E4C22C53-E5AD-4CA3-901F-067A29A11C48Q5206280-AA97BA73-0251-472C-863E-3C95BE54E4A0Q52155313-A72B1C48-3202-47F6-AC42-9C3DA75ABC5DQ52392355-44E718B7-A3C9-4050-A64D-4770D9AE7663Q52392673-97AEC40E-08E8-47E3-9744-BE467F92B405Q52609889-8B33F615-6CC1-46E1-9425-71075D25FE58Q54076889-680CFD2B-4536-44EC-84BE-BFE08B02BB64Q54583071-C7661C3B-65E0-44A8-BA89-9E08BA3ECE9BQ54583380-6CC9B9DF-7A69-410F-847C-D2D13E2C891DQ54583395-8A0CDA34-F81A-4608-8091-3628C9598332Q54603004-171E0BB9-5D73-4B42-B653-64765718443EQ54603178-703DE15E-5B4C-410E-A53D-CDD285047CC6Q54603866-8934C6E4-4B19-49F2-B808-8447C77419CAQ54604500-FA768868-FDB0-4052-A4F2-6177C2FD4639
P1343
Q28076097-7A5C080D-6FBF-4B42-978D-AC860EB3D111Q28076871-1E539727-C1B5-437A-A026-84616A0EECC0Q28586368-F75741D5-1906-4E00-9984-8B5002B37CF5Q28656335-8F873C32-2B62-4413-8BA5-7A6BAAF51BF1Q30241056-B8039FB6-7CF5-46C3-9ED8-8DEFA8698887Q31126284-0A14BE00-5E2F-4AB6-8171-58662ABB13AAQ31138564-4337C03D-77E6-41D2-AF01-ED9B7FD226BAQ33578398-8673F101-B09B-477F-92B8-DADEE36B70BCQ33807632-EC82FE56-8DA8-4144-BC1F-5D6AF103DE37Q33903831-27B7CBA7-2E32-4481-B121-8D76694105D6Q36309864-DB3F8FDB-B5BC-4F49-8A7A-F8B0CEE2AC76Q36348889-D1C4AB11-7ADC-473D-AB50-C270FA4E1CA7Q36358010-67B2344A-71B4-43F4-89B8-651880FD895BQ37556877-ED1033E9-419C-42E4-B3AE-157302345695Q37609851-AB607EA7-11FB-48B8-903F-BAA4E1D9A502Q37702327-2CD5E5F6-603E-4304-8CE2-71CDBCFD88EAQ37706353-BF3BFE37-F10C-4733-9A76-55BC405B99C3Q38400577-443C38F0-4ACF-4004-8054-3EB5590648E8Q38599419-F2737E4E-51B2-4787-B536-ADD85E0A6256Q38602104-AC7CAC84-333A-443A-B237-52087508413CQ38628538-BCAF4E33-BC46-4476-89B5-4D94A34CB919Q38646090-35CE72DA-F5AB-47F4-9478-162E6A699252Q38646272-44162436-02A1-4620-9CEE-6D4EBFF5353DQ38646648-30C11280-E388-4153-8108-3E701D84931CQ38681800-36C10469-6FE6-49DC-AE22-DE2717A05131Q38699958-0C8FEB71-ECCC-4EA5-A202-C93D70C2997AQ38704070-D4C4A1B8-C8D8-4DE5-980F-A405F217D737Q38709651-6AB3EB54-4583-4E53-B5D6-10A46D88C6C4Q38712272-80DA236D-A421-435C-A6F9-799E15FD37FCQ38720911-8E49C32B-562B-45E4-A8CF-7C9498FD8BF1Q38728970-E002C944-4F0F-4CA9-B3A7-9B9E3F5F8808Q38747872-9EDD35CE-62B4-4B08-AC93-391BBE4154F0Q38885294-20A077A4-D35C-4C93-A168-B6CD507C95F9Q39188703-71044CE0-CB09-42FC-A4C1-061267C35433Q39314677-A84AA1F7-AE5E-4980-A8BA-A72F448EA655Q40958676-CA4DDDCC-ED11-4458-AEF9-E7C73ED0F2AFQ41023790-72ACD0DC-D31A-451E-A311-FCF24E912A2DQ41156013-2D547920-5E9C-4FB9-892B-3980A005F273Q41201459-0D6D58F3-F60B-4BAD-8CA7-B1154687784BQ41536811-FBE23EB8-9F27-4968-9C99-D7DD011253BB
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 05 July 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A Landscape of Pharmacogenomic Interactions in Cancer.
@nl
A landscape of pharmacogenomic interactions in cancer.
@en
type
label
A Landscape of Pharmacogenomic Interactions in Cancer.
@nl
A landscape of pharmacogenomic interactions in cancer.
@en
prefLabel
A Landscape of Pharmacogenomic Interactions in Cancer.
@nl
A landscape of pharmacogenomic interactions in cancer.
@en
P2093
P2860
P4510
P50
P1433
P1476
A Landscape of Pharmacogenomic Interactions in Cancer
@en
P2093
Cyril H Benes
Daniel A Haber
Daniel J Vis
David Tamborero
Ewald van Dyk
Graham R Bignell
Heshani de Silva
Jinhua Wang
Laura Richardson
P2860
P304
P356
10.1016/J.CELL.2016.06.017
P407
P50
P577
2016-07-07T00:00:00Z